{"id":347313,"date":"2019-03-26T10:55:02","date_gmt":"2019-03-26T10:55:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=347313"},"modified":"2019-03-26T10:55:02","modified_gmt":"2019-03-26T10:55:02","slug":"creative-biolabs-releases-three-antibodydrug-conjugation-strategies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-releases-three-antibodydrug-conjugation-strategies_347313.html","title":{"rendered":"Creative Biolabs Releases Three Antibody-drug Conjugation Strategies"},"content":{"rendered":"

New York, March 26 <\/strong>With years of experience in antibody-drug conjugates (ADCs) development, Creative Biolabs releases three different antibody-drug conjugation strategies to support global clients who are looking for efficient approaches for the development of site-specific ADCs.<\/p>\n

 <\/p>\n

Designing of an ADC is an elaborate process that involves careful planning, meticulous execution, and intensive trouble-shooting. Effective conjugation approaches will greatly increase the chance to generate highly customized ADCs in a timely and cost-efficient way. Therefore, depending on a deep understanding of conjugation chemistry<\/a>, Creative Biolabs offers lysine-based conjugation strategy, cysteine-based conjugation, and carbohydrate-based conjugation.<\/p>\n

 <\/p>\n

1 Lysine-based conjugation<\/strong><\/p>\n

In ADC development, lysine conjugation<\/a> is one of the most widely used non-specific conjugation strategies, which occurs on reactive amine side chains of lysine residues due to their good nucleophilicity. It is a simple process without requiring any form of antibody engineering or modification, suitable for the conjugation to both the Fab region and full-length IgG. Multiple conjugation sites enable the sufficient loading of payload drugs and its high chemical versatility can incorporate a variety of cytotoxic agents into antibodies.<\/p>\n

 <\/p>\n

2 Cysteine-based conjugation<\/strong><\/p>\n

Cysteine residues serve essential roles in protein structure and function due to their highly reactive thiol side chains that form inter or intra molecular di-sulfide bonds to enable correct protein folding and provides an appealing route for conjugating toxic agents to antibodies. There exist two kinds of cysteine-based conjugation strategies. Conjugation based on inter-chain cysteines generates ADCs with heterogeneous conjugation sites and a different number of drugs attached, resulting in a drug to antibody ratio (DAR) ranging from 0, while conjugation based on engineered cysteines, designated as EnCys-mAb, generates antibody-drug conjugates with improved homogeneity. Besides the advantages of easy operation and site-specific ability, cysteine conjugation<\/a> offers flexible choices for generating either non-specific or site-specific ADCs.<\/p>\n

 <\/p>\n

3 Carbohydrate-based conjugation<\/strong><\/p>\n

Carbohydrate-based conjugation is unlikely to impair the antigen binding affinity and potentially serves as an excellent alternative for site-specific antibody-drug conjugate (ADC) generation. There are three elaborate strategies in Creative Biolabs to target carbohydrate moiety for the conjugation of payload drugs: (1) glycan chemical oxidation, (2) glycan enzymatic and chemo-enzymatic modification, and (3) carbohydrate moiety metabolic engineering. These strategies are suitable for the conjugation to glycosylated full-length IgG without reducing antigen binding affinity, and can be achieved by versatile approaches, including chemical, enzymatic, chemo-enzymatic, and metabolic engineering methods.<\/p>\n

 <\/p>\n

Aiming at helping clients with various ADC development projects, Creative Biolabs <\/strong>provides the most comprehensive antibody modification and conjugation strategies in a timely and cost-efficient manner. More details can be found at https:\/\/www.creative-biolabs.com\/adc<\/a>. <\/p>\n

 <\/p>\n

 <\/strong><\/p>\n

About Creative Biolabs<\/strong><\/p>\n

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production\/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.<\/p>\n

 <\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs<\/a>
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/adc<\/a><\/p>\n

 <\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, March 26 With years of experience in antibody-drug conjugates (ADCs) development, Creative Biolabs releases three different antibody-drug conjugation strategies to support global clients who are looking for efficient approaches for the development of site-specific ADCs.   Designing of … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-347313","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/347313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=347313"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/347313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=347313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=347313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=347313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}